UK markets closed
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • FTSE 250

    22,734.13
    +125.37 (+0.55%)
     
  • AIM

    1,249.65
    +3.03 (+0.24%)
     
  • GBP/EUR

    1.1648
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • BTC-GBP

    25,224.33
    -1,365.39 (-5.14%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.36 (+0.04%)
     
  • CRUDE OIL

    70.78
    +0.49 (+0.70%)
     
  • GOLD FUTURES

    1,879.50
    -16.90 (-0.89%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     
  • HANG SENG

    28,842.13
    +103.25 (+0.36%)
     
  • DAX

    15,693.27
    +122.05 (+0.78%)
     
  • CAC 40

    6,600.66
    +54.17 (+0.83%)
     

Chronic Pain Clinical Trial Pipeline Report 2021: Global Clinical Trial Stages, Drug Mechanism Classes, Companies, Short-term Launch Highlights

·2-min read

Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Chronic Pain Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

The latest report Chronic Pain Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Chronic Pain market. It covers emerging therapies for Chronic Pain in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Chronic Pain pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Chronic Pain pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Chronic Pain pipeline products by the company.

Short-term Launch Highlights:
Find out which Chronic Pain pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Chronic Pain phase 3 clinical trial pipeline products

  • Chronic Pain phase 2 clinical trial pipeline products

  • Chronic Pain phase 1 clinical trial pipeline products

  • Chronic Pain preclinical research pipeline products

  • Chronic Pain discovery stage pipeline products

  • Chronic Pain pipeline products short-term launch highlights

Key Topics Covered:

1. Chronic Pain Pipeline by Stages

2. Chronic Pain Phase 3 Clinical Trial Insights

3. Chronic Pain Phase 2 Clinical Trial Insights

4. Chronic Pain Phase 1 Clinical Trial Insights

5. Chronic Pain Preclinical Research Insights

6. Chronic Pain Discovery Stage Insights

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/e4lqds

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900